<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The incidence of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) is rising worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Liver-derived fibroblast growth factor (FGF)-21 affects <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to analyze the predictive value of FGF-21 on the incidence of T2DM and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic Syndrome</z:e> Berlin Potsdam (MeSyBePo) recall study includes 440 individuals </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> metabolism was analyzed using an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test, including insulin measurements </plain></SENT>
<SENT sid="5" pm="."><plain>FGF-21 was measured using enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="6" pm="."><plain>Primary study outcome was <z:mp ids='MP_0002055'>diabetes</z:mp> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> incidence and change of <z:chebi fb="105" ids="17234">glucose</z:chebi> subtraits </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: During a mean follow-up of 5.30 Â± 0.1 years, 54 individuals developed the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, 35 developed T2DM, and 69 with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance at baseline progressed to impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, defined as impaired fasting <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>, or T2DM </plain></SENT>
<SENT sid="8" pm="."><plain>FGF-21 predicted incident <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (lnFGF-21 odds ratio [OR] 2.6 [95% CI 1.5 - 4.5]; P = 0.001), T2DM (2.4 [1.2-4.7]; P = 0.01), and progression to impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism (2.2 [1.3 - 3.6]; P = 0.002) after adjustment for age, sex, BMI, and follow-up time </plain></SENT>
<SENT sid="9" pm="."><plain>Additional adjustment for waist-to-hip ratio, systolic blood pressure, <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, and fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> did not substantially modify the predictive value of FGF-21 </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: FGF-21 is an independent predictor of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and T2DM in apparently healthy Caucasians </plain></SENT>
<SENT sid="11" pm="."><plain>These results may indicate FGF-21 resistance precedes the <z:hpo ids='HP_0003674'>onset</z:hpo> of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and T2DM </plain></SENT>
</text></document>